- EUDRACAP® colon capsules target the ileo-colonic region for precise drug delivery.
- The capsules are designed for sensitive actives like live biotherapeutics, RNA, and biologics.
- Over 700 oral drug development programs use novel active ingredients.
- EUDRACAP® platform includes enteric, Select, and preclinic variants.
Introduction
Evonik has introduced EUDRACAP® colon functional capsules, produced under good manufacturing practice (GMP), at CPHI Frankfurt. These capsules are designed for clinical and commercial use, targeting the ileo-colonic region.
Innovative Drug Delivery
EUDRACAP® colon is the first ready-to-fill capsule specifically aimed at delivering sensitive active ingredients, such as live biotherapeutic products (LBPs), RNA, and biologics, to the ileo-colonic region. This innovation addresses the growing demand for precise drug delivery, simplifying oral drug development by eliminating complex formulation steps.
Market Impact
The introduction of these capsules is expected to accelerate clinical timelines and facilitate the market entry of innovative therapies. Currently, there are over 700 oral drug development programs utilizing novel active ingredients, which constitute about a third of all new oral drug developments in the pipeline.
Platform Expansion
EUDRACAP® colon is part of Evonik's expanding platform of functional capsules for oral drug delivery, which includes EUDRACAP® enteric for targeted drug release in the upper small intestine, EUDRACAP® Select for tailored CDMO services, and EUDRACAP® preclinic for early-stage development. This platform is built on the trusted EUDRAGIT® polymers, used in formulations across 80 countries and cited in over 23,000 patents.
